Dose finding and safety analysis of inecalcitol in combination with docetaxel-prednisone regimen in hormone-refractory prostate cancer (HRPC) patients (pts)

被引：0
|
作者：
Medioni, J. [1 ]
Deplanque, G. [2 ]
Maurina, T. [3 ]
Ferrero, J. M. [4 ]
Rodier, J. M. [5 ]
Raymond, E. [5 ]
Allyon, J. [1 ]
Kalla, S. [2 ]
Dufour-Lamartinie, J. F. [6 ]
Oudard, S. [1 ]
机构：
[1] Hop Europeen Georges Pompidou, Paris, France
[2] Ctr Hosp St Joseph, Paris, France
[3] Ctr Hosp Univ Jean Minjoz, Besancon, France
[4] Ctr Antoine Lacassagne, F-06054 Nice, France
[5] Hop Beaujon, Clichy, France
[6] Hybrigenics, Oncol, Paris, France
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)71408-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：415 / 415
页数：1
相关论文
共 50 条
  • [21] Phase II randomized trial of docetaxel plus estramustine (BE) versus docetaxel (D) in patients (pts) with hormone-refractory prostate cancer (HRPC): A final report.
    Eymard, JC
    Joly, F
    Priou, F
    Zannetti, A
    Ravaud, A
    Kerbrat, P
    Mousseau, M
    Paule, B
    Touze, F
    Ecstein-Fraisse, E
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 407S - 407S
  • [22] Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer
    Dagher, R
    Ning, L
    Abraham, S
    Rahman, A
    Sridhara, R
    Pazdur, R
    CLINICAL CANCER RESEARCH, 2004, 10 (24) : 8147 - 8151
  • [23] Actual chemotherapeutical possibilities in hormone-refractory prostate cancer (HRPC) patients
    Prezioso, Domenico
    Galasso, Raffaele
    Di Martino, Mario
    Iapicca, Gennaro
    Annunziata, Emanuele
    Iacono, Fabrizio
    ANTICANCER RESEARCH, 2007, 27 (02) : 1095 - 1104
  • [24] A randomized dose-finding phase II study of ifosfamide (IF) in metastatic hormone-refractory prostate cancer (HRPC).
    Hervonen, P
    Lehtinen, T
    Tammela, TLJ
    Kellokumpu-Lehtinen, P
    ANNALS OF ONCOLOGY, 2000, 11 : 76 - 76
  • [25] Docetaxel plus prednisone in patients with metastatic hormone-refractory prostate cancer: an Italian clinical experience
    Cicero, G.
    De Luca, R.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2011, 15 (03) : 325 - 331
  • [26] Dose-finding study of weekly docetaxel plus estramustine in patients with hormone-refractory metastatic prostate cancer
    Coccaro, M
    Tartarone, A
    Romano, G
    Ardito, R
    Di Renzo, N
    TUMORI, 2005, 91 (04) : 314 - 316
  • [27] A randomised dose-finding phase II study on ifosfamide in metastatic hormone-refractory prostate cancer (HRPC)
    Hervonen, P
    Lehtinen, T
    Tammela, TL
    Kellokumpu-Lehtinen, P
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2002, 21 (02) : 177 - 180
  • [28] Prospective Randomized Study Comparing Docetaxel, Estramustine, and Prednisone With Docetaxel and Prednisone in Metastatic Hormone-Refractory Prostate Cancer
    Machiels, Jean-Pascal
    Mazzeo, Filomena
    Clausse, Marylene
    Filleul, Bertrand
    Marcelis, Luc
    Honhon, Brigitte
    D'Hondt, Lionel
    Dopchie, Catherine
    Verschaeve, Vincent
    Duck, Lionel
    Verhoeven, Didier
    Jousten, Peter
    Bonny, Marie-Alix
    Moxhon, Anne-Marie
    Tombal, Bertrand
    Kerger, Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (32) : 5261 - 5268
  • [29] Clinical experience of docetaxel in combination with prednisolone and zoledronic acid for hormone-refractory prostate cancer (HRPC): A Bangladesh perspective.
    Hoque, E.
    Karim, S.
    Reza, M. D. S.
    Ahmed, T. U.
    Adnan, R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [30] Phase II study of CC-4047 in patients (pts) with metastatic hormone-refractory prostate cancer (HRPC)
    Floissac, M
    Knight, R
    Levin, A
    Glode, LM
    Crawford, ED
    Amato, RJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 410S - 410S
12345